The biopharma view from the continent
We’re live in London once again with our 5th annual series taking a close look at some of the most prominent players in Europe’s biopharma industry. Endpoints News Editor John Carroll and SVB’s Nooman Haque once again will host a slate of panels and fireside chats to illuminate the latest on financing, R&D trends and regulatory issues that are central to drug development. You can buy a ticket for the afternoon events October 12, or simply sign up for streaming the full lineup, beginning that morning.
Fireside Chat with Marcus Schindler & John Carroll
Marcus Schindler
Executive Vice President for Research & Early Development and CSO
Novo Nordisk
John Carroll
Founder & Editor
Endpoints News
Building a better CAR
The first generation of CAR-Ts helped revolutionize the treatment of liquid cancers, offering some jaw-dropping data and presenting big challenges in manufacturing and delivery. Now a new generation of cell therapies is taking shape in the clinic that promise to not only be easier to manufacture, but could also break down barriers on exhaustion, durability and more. We’ll talk with the transatlantic pioneers who are moving this field forward.
Alain Maiore
Co-Founder & Chief Operating Officer
Mnemo Therapeutics
Joanna Brewer
Chief Scientific Officer
Adaptimmune
Rob Igarashi
Head of Discovery & Pre-Clinical Development in Global Oncology Research
Sanofi
Eric Vivier
Chief Scientific Officer
Innate Pharma
Cedrik Britten
Chief Medical Officer
Immatics
John Carroll
Founder & Editor
Endpoints News
moderator
David Chia
Senior Business Development Manager, United Kingdom
Novotech
presenting speaker
Fireside Chat with Steve Bates & John Carroll
Steve Bates
CEO
BIA
John Carroll
Founder & Editor
Endpoints News
Faster, better, cheaper? What’s next for mRNA?
Some of the leaders in mRNA are driving the next round of innovation in the field. We’ll be talking to some of the top scientists in Europe who are tackling better delivery vehicles, better and faster vaccines with a look at the pipeline of translational therapies that promise to keep the mRNA revolution moving forward.
Jean-Francois Toussaint
Global Head of Research & Development Vaccines
Sanofi
Patrick Baumhof
Senior Vice President of Technology
CureVac
Dan Peer
Vice President for Research and Development, and Director of the Laboratory of Precision Nanomedicine
Tel Aviv University
Kenneth Chien
Professor Karolinska Institutet; Co-Founder Moderna and Board member eTheRNA
John Carroll
Founder & Editor
Endpoints News
moderator
Wai Lam W. Ling
VP Scientific Advisory
Catalent
presenting speaker
Welcome remarks
Nooman Haque
MD, Life Sciences and Healthcare
Silicon Valley Bank
John Carroll
Founder & Editor
Endpoints News
Surviving a Broken Market
The unprecedented boom that lifted biotech during the pandemic gave way to a brutal bust that eviscerated share prices and dried up generalist interest in the industry. We’ll gather a group of the continent’s top public biotech CEOs to discuss their strategy for weathering the storm while pushing ahead with their most critical R&D plans.
Andrew Hopkins
Chief Executive Officer & Founder
Exscientia
Kate Bingham
Managing Partner
SV Health Investors
Denise Scots‑Knight
Chief Executive Officer
Mereo BioPharma Group, plc
Adrian Rawcliffe
Chief Executive Officer
Adaptimmune
John Carroll
Founder & Editor
Endpoints News
moderator
Fireside Chat with Susan Galbraith and John Carroll
Susan Galbraith
Executive Vice President, Oncology R&D
AstraZeneca
John Carroll
Founder & Editor
Endpoints News
Navigating capital headwinds
Private and public markets are riven by turbulence which shows no sign of abating. The biotech sector itself has seen challenges from US healthcare reform to wider political and macroeconomic factors causing stress to all parts of the economy. Finding a clear financial strategy is unnerving and complex and our panellists will do their best to shed light on how to manage in these times.
Katya Smirnyagin
Senior Partner (Life Sciences)
Oxford Science Enterprises
Maina Bhaman
Partner, Capital Strategy
Sofinnova Partners
Jonathan Hepple
Founder Partner
Rosetta Capital Ltd
Nooman Haque
MD, Life Sciences and Healthcare
Silicon Valley Bank
moderator
Reception with drinks & hors d'oeuvres
We’ll be ending the event on October 12 with drinks and a mixer on the Silicon Valley Bank balcony overlooking London. Endpoints Editor John Carroll and Silicon Valley Bank’s Nooman Haque will be on hand for direct discussions and a chance to catch up on you and your companies. This is always the most fun we have at this event, and one we look forward to eagerly.